The investigation of the Nightingale account

The investigation of the Nightingale account turns an apparently private act of generosity into a line of inquiry through the finances of Harkness Pharmaceuticals. It begins when Don Challenor and Blake try to understand why Andrew Glasson directed their attention to Holly Walsh, whose multiple sclerosis is being treated with an expensive experimental drug. Their inquiries uncover an anonymous account at Credit Suisse, a benefactor using the name Luscinia, and competing reasons to protect or investigate the arrangement. The account remains small beside the billions allegedly diverted from Harkness’s business, but its uncertain provenance makes it an early, concrete sign of money moving beyond ordinary scrutiny.

From Holly Walsh’s treatment to the account

Don Challenor first reads Holly Walsh’s blog posts while parked near Andrew Glasson’s house. They describe her life with multiple sclerosis, her partner Anna Marchant, and the improvement she attributes to Ditrimantelline, an experimental medicine she calls the Wonderpill. Holly says the treatment is extraordinarily expensive and that an anonymous benefactor makes it possible. Her gratitude is public, but the donor’s identity and reason for helping her are not. Don finds nothing in the posts to explain why Andrew Glasson had drawn attention to Holly, so the online account becomes a lead rather than an answer.

When Don and Blake later visit Holly, Blake notices the medicine in the bathroom cabinet. Alongside Elixtris face cream and body scrub are cartons of Ditrimantelline, marked as a daily ten-milligram dose and carrying a warning against driving, operating machinery, or drinking alcohol. The manufacturer is Harkness Pharmaceuticals. The packaging ties Holly’s personal treatment directly to Jack Harkness’s company, while the presence of Elixtris brings another Harkness product into the same domestic setting. The medicine is not merely an abstract expense: Holly’s health and her ability to continue treatment depend on a supply that comes from somewhere.

Holly confirms that the anonymous funding has made her wonder whether Jane Glasson might be responsible. She cannot accept that explanation, however, because it would require her to believe Jane deliberately abandoned her family and friends when she disappeared twenty-two years earlier. Anna Marchant is even more determined to discourage the connection. She argues that some benefactors choose to help without recognition, and that Holly’s positive outlook matters to her welfare. The investigation therefore encounters a conflict between the investigators’ search for a connection to Jane and the household’s concern that probing the gift might put Holly’s treatment at risk.

Luscinia and the limits of disclosure

Holly explains that the money comes from an account at Credit Suisse in London, held in the name Nightingale. The bank will not say whether Nightingale is a personal or company name. The donor first contacted Holly by email under the name Luscinia, Latin for nightingale. She presented herself as someone working in pharmaceuticals, appalled by the cost of effective drugs, and offered to supply Ditrimantelline after reading Holly’s accounts of living with multiple sclerosis. She insisted on anonymity because disclosure could get her into trouble. Holly had heard that the drug had been successful in the United States and accepted the offer; Anna Marchant confirms that the treatment has transformed Holly’s condition.

After initially resisting further questioning, Anna Marchant offers Don and Blake additional information that she believes will settle whether Jane is involved. She says she met Luscinia at a coffee shop in O’Hare Airport. The woman was an Asian American in her mid-thirties who had inherited a fortune from her father and used some of it to help people. Anna understood that Luscinia’s wealthy husband might disapprove of her charitable activity. Luscinia had agreed to meet because she feared Anna might keep investigating and inadvertently bring the donations to his attention. She was supporting other beneficiaries as well as Holly.

Anna also recounts the reason Luscinia gave for her philanthropy: one of her brothers died as a child because he lacked proper medical treatment, while their mother, after the parents’ divorce, could not afford the drugs he needed. That history gives the anonymous payments a personal explanation, but not a publicly verifiable identity. Anna says she glimpsed Luscinia’s name on a credit card and later searched for her husband and father, yet refuses to pass those details to Don and Blake. She considers the donor entitled to privacy because of her generosity, and fears that the investigators’ continued inquiries could endanger Holly’s health.

A creditor’s inquiry and a wider financial mystery

The question returns when Holly contacts Don after Anna Marchant has gone out. She discloses that a man recently approached her and subsequently visited, knowing that she received money from the Nightingale account at Credit Suisse. The man wanted to know why the account was paying her. Holly says he was a private investigator working for some of Jack Harkness’s creditors. He did not claim to be investigating Jane Glasson, and Holly judged that Jane was not the reason for his interest. His attention instead raises a practical concern: if Luscinia is a Harkness employee diverting company funds to pay for medication, the payments might be stopped. The investigator reassured Holly that nothing was likely to happen until Harkness’s case had passed through the American courts, a process that could take years if he were extradited.

The account’s significance changes when Keith Perkins and Clarice Dow explain the allegations against Harkness. Quintagler Industries alleges that, over several years, Harkness diverted funds through subsidiaries of shell companies he ultimately owned. Those companies are also alleged to have supplied money for bribes to doctors. The companies are based in tax havens with limited disclosure requirements, leaving investigators unable to establish where much of the money went. In that context, the Nightingale account is described as a one-off, opened in London and involving only peanuts compared with the billions Quintagler says may have been taken. The investigators know that Holly’s account exists; they do not know whether it was funded with corporate money or how it relates to the wider alleged diversions.

That uncertainty sits against Harkness Pharmaceuticals’ history of rapid growth. Jack Harkness entered the company Furgler Gesellschaft through his relationship with Lenore Furgler, later acquired it from her, and renamed it Harkness Pharmaceuticals. The company’s growth accelerated through research and products including Elixtris, followed by a partnership with Quintagler that financed acquisitions across several regions. The account investigation does not establish that this corporate history explains Luscinia’s payments. It does, however, show why even a relatively small, anonymous transfer attracts attention when Harkness’s creditors are searching for money whose destination remains obscure.

Unrecorded research and the later revelation

Later disclosures enlarge the financial picture without resolving the Nightingale account’s source. In a discussion with Filippo Crosetti, questions arise about Harkness Pharmaceuticals funding extensive work in nanotechnology and bioelectronics with no obvious connection to pharmaceutical products. Crosetti is also confronted with the claim that he served as a conduit for a vast additional package of funding with no booked source, which the questioner believes Jack Harkness arranged. These details echo the earlier problem of money concealed behind opaque structures, but the evidence does not identify the Nightingale account as a channel for this research funding.

The subsequent revelation is that Harkness’s investment in pharmaceuticals served a purpose beyond ordinary drug development. He, Astrid, and Crosetti worked on a nanobot programme intended to address the mass extinction of species. The programme placed nanobots in Harkness Pharmaceuticals drugs and cosmetics, as well as in pesticides used on crops and antibiotics given to animals. Products named include Ditrimantelline, Elixtris, and Fenextris; exposure reached people through medication, food production, and products absorbed through the skin. This disclosure recasts the company’s unusual research spending as part of a concealed, large-scale project. It does not establish that the Nightingale donations paid for that project, and the account’s precise source remains unresolved.

Significance

The inquiry moves from a patient’s dependence on a medicine to the institutional question of who controls its supply and who pays for it. Holly’s treatment is both demonstrably beneficial to her and financially vulnerable: she relies on an anonymous donor, while the donor’s secrecy is defended as necessary to protect her from personal and corporate consequences. The Nightingale name appears to promise an identifiable trail, but the account’s holder is undisclosed, Luscinia withholds her identity, and Anna Marchant refuses to make her discoverable.

The account is therefore a limited clue rather than a solution. It exposes a point of contact between private aid and the distressed finances of Harkness Pharmaceuticals, while the larger inquiry reveals alleged shell-company transfers and substantial research funding without a booked source. The eventual nanobot revelation supplies a hidden purpose for some of the company’s research, not a proven explanation for Holly’s payments. That distinction preserves the central uncertainty: the treatment’s human benefit is clear, but the route by which the money reaches it remains obscured.